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III pattern and in them interestingly normal ECG was seen in 50 %
and in another 50 % LVHwith no strain was noted. QS pattern was
seen in 30.4 % and left atrial abnormality in 21.6 %. TYPE IV pattern
was seen in 17 patients and in which 16 patients (94.1% ) had a
characteristic V4 R wave > 20 mm with deep T inversions in pre-
cordial leads. This unique pattern of electrocardiographic findings
had a sensitivity of 93 % for TYPE IV HCM.
Conclusions: Both symmetrical and asymmetrical hypertrophy
was noted in cases of HCM with or without obstruction. In cases
with asymmetrical hypertrophy (ASH), the hypertrophy was pre-
dominantly distributed either in the upper or lower septum,
lateral wall and posterior wall. The anterior ventricular septum
was predominantly was the most frequently hypertrophied
segment of the left ventricle seen in 78.3 %, followed by posterior
part of the septum in 58.33 %, and lateral free wall in 35 %. Pos-
terior free wall was preferentially spared and was thickened in
only 5 % of the patients. Except for the classical pattern of V4 R
wave of more than 20 mm with deep T inversions in precordial
leads in 94.1 % of TYPE IV hypertrophy, no other singular echo-
cardiographic pattern seemed to be very classical for the specific
distribution of hypertrophy.
Escherichia coli sepsis as a precipitant of stress
cardiomyopathy: A systematic review
M. Subramanian, P. Arthur, S. Gopalan, S. Ramadurai
Sri Ramachandra University, Chennai, India
Background: Stress cardiomyopathy (SC) is a novel cardiac syn-
drome characterized by peculiar, transient left ventricular
dysfunction in the absence of significant coronary occlusion.Ex-
acerbations of chronic medical conditions and sepsis are common
precipitants that precede the “myocardial stunning.”There is ev-
idence that inflammatory cytokines released by Escherisca coli
and lipopolysaccharide administration cause decreased cardiac
myofilament responsiveness and contractility.
Methods: The present systematic review aimed to report an
updated case series of SC precipitated by E.coli sepsis in an
attempt to summarize their demographic and clinical character-
istics. A systematic search through Medline archives accessed by
Pudmed (1950-2013) for all such case reports matching our inclu-
sion criterion was performed. Overall, four such cases were
eligible and we included our patient with SC with E.coli sepsis as
the fifth report. Demographic, clinical, electrocardiographic, and
echocardiographic characteristics were compared and evaluated.
Results: There was a greater male predominance with an average
age of 56 years. The most common ECG abnormalities were ST
segment elevation in lateral leads (40%) and anterior leads (60%).
There were no fatal outcomes in the cases reported in this anal-
ysis. The average time to achieve recovery of clinical, biochemical,
and echocardiographic abnormalities was 17 days.
Conclusion: In comparison to most cases of SC reported in liter-
ature due to other stressors, E.coli sepsis SC are younger and show
a greater male predominance. Other unique characteristics of this
subset of patients are ST segment elevation in lateral leads,
modest increase in troponin levels, and relatively faster complete
recovery. Patients in whom E.coli sepsis is the precipitating factor
of SC have a different spectrum of clinical, biochemical, and
electrocardiographic changes. A high index of clinical suspicion is
essential in the diagnosis and treatment of these patients.
Effect of Ivabradine in patients with heart failure
in whom beta blockers were contraindicated
Aditya Chaudhary, Anurag Rawat
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Background: Heart failure is associated with high mortality and
morbidity. Tachycardia is an important risk factor for adverse out-
comes. Betablockers are important part of heart failure manage-
ment as they reducesmortality significantly.Weassessed the effect
of heart-rate reduction by the ivabradine on outcomes in heart
failure in patients in whom beta blockers were contraindicated.
Methods: Patients were eligible for participation in this study if
they had symptomatic heart failure with left-ventricular ejection
fraction of 35% or lower, were in sinus rhythm with heart rate
more than 75 bpm who were admitted with aggravation of
symptoms, and beta blockers were contraindicated. Patients were
given ivabradine titrated to a maximum of 7$5 mg twice daily or
matching placebo The primary endpoint was the composite of
cardiovascular death or hospital admission for worsening heart
failure.
Result: We evaluated 1500 patients of heart failure from Januaury
2010 till June 2014.Out of 1500 patients, 800 patients were ineli-
gible for betablockers in view of low blood pressure. Out of rest 700
patients, 350 patients received ivabradine and 350 patients were
given placebo. 60% patients were males and rest were females.
They were followed for more than two years. There was no sig-
nificant difference in mortality between the two groups as 24
patients from ivabradine and 27 patients from placebo group
expired ( p - non significant). There was not much difference in
hospital admissions due to worsening of heart failure. (82 patients
from ivabradine group and 87 patients from placebo group got
admitted.), No significant side effects were noted with ivabradine.
Conclusion: There was no significant difference in mortality and
morbidity with ivabradine therapy in patients with heart failure in
whom betablockers were contraindicated. Hospitilization was
more or less same in both the groups.
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Background: Ivabradine, selective If channel blocker, has been
shown to reduce recurrent hospitalization due to worsening of
heart failure. Role of this agent on left ventricular function in
patients with ischemic heart failure is still unexplored.
Aims and objectives: This study was planned to assess the effects
of addition of ivabradine to optimal medical therapy(OMT) in
patients of ischemic heart failure with systolic dysfunction on Left
ventricular function, Exercise duration, Serum Brain Natriuretic
Peptide (BNP) levels and Health-related quality of life.
Methods: In this open-label, randomized, a total number of 158
patients of stable, ischemic heart failure were included and were
randomly assigned into OMT group (n¼80) and ivabradine group
(n¼78). Baseline assessments included assessment of Left ven-
tricular dimension and Left ventricular ejection fraction (LVEF),
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Exercise duration (in seconds) by exercise test and QOL score
assessment by Kansas City Cardiomyopathy Questionnaire
(KCCQ) and Serum BNP level. In ivabradine group, patients were
started on ivabradine5 mg in twice daily dose, in addition to OMT.
Patients were followed up for 6 months. At the end of six months,
LV dimensions, LV function, serum BNP levels, QOL and exercise
duration were re-assessed.
Results: At six months, though there was significant reduction of
heart rate (70.60 ± 5.06 vs 91.33 ±8.9, p < 0.0001) and improvement
of QOL score (p¼ 0.004) and NYHA functional Class(p¼ 0.007) with
ivabradine group compared to OMT group, ivabradine failed to
show significant improvement in LVEF(35 ±3.71 vs 33±4.24, p¼NS),
Exercise duration (320 ±130.6 vs 311.79 ±103.60, p¼ 0.663) and BNP
level (248.64 ±175.70 vs 312.57 ±222.6, p¼ 0.22). Subgroup analysis
showed significant improvement in LVEF (35.71±2.98 vs 33.50
±3.73, p¼0.003) in patients with ivabradine who achieved heart
rate less than 70(n¼25). No significant adverse effects on ivabra-
dine therapy were noted at the end of six months.
Conclusions: Ivabradine when added to optimal medical therapy,
in NYHA Functional Class and QoL in patients with ischemic heart
failure. Improvement of Left ventricular function also occurs in
presence of adequate heart rate lowering (HR<70/ min).
Efficacy of levosimendan compared with
dobutamine in low-output heart failure
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Background: Levosimendan, a calcium channel sensitiser, im-
proves myocardial contractility without causing an increase in
myocardial oxygen demand. This study was done to compare the
effects of levosimendan and dobutamine on clinical outcome in
patients with low-output heart failure.
Methods: Patients were eligible for participation in this study if
they had symptomatic low output heart failure. Overall 175 pa-
tients were enrolled in this study. Under continuous haemody-
namic monitoring, an initial loading dose of levosimendan of 24
mcg/kg was infused over 10 min, followed by a continuous infu-
sion of 0.1 mcg/kg/min for 24 h. Dobutamine was infused for 24 h
at a dose of 5 mcg/kg/min. The primary endpoint was the pro-
portion of patients with clinical improvement.
Results: 100 patients were given levosimendan and 75 dobut-
amine. The clinical improvement was achieved in 28 (28%) levo-
simendan-group patients and 15 (20%) in the dobutamine group
p¼0.02). At 6 months, 20 (20%) levosimendan-group patients had
died, compared with 25 (33%) in the dobutamine group p¼0.02).
Conclusion: In patients with severe, low-output heart failure,
levosimendan improved clinical outcome more effectively than
dobutamine. Lower mortality was noted in levosimendan group
upto 6 months.
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Background: A cardiac syndrome of “apical ballooning” is being
increasingly encountered in routine cardiology practice as it
usually mimics acute coronary syndrome at presentation and
therefore mandates demonstration of non critical coronary artery
disease on coronary angiogram for diagnostic confirmation but its
feasibility is scarce in our country. We sought to assimilate clin-
ical, echo-cardiographic and angiographic features of this syn-
drome at a tertiary care setting from carefully selected cases of
apical ballooning and develop an algorithmwhich should help the
emergency physician in making a simpler bedside diagnosis of
this syndrome.
Methods: Patients apparently admitted with acute coronary syn-
drome but subsequently given the diagnosis of transient LV apical
ballooning syndrome at our institution from January 2011 to June
2013 were taken prospectively.
Results: Twelve patients were enrolled, mean age was 50±12
years, 10 (83%) were women. Trigger events could be identified in
9(75%) patients (emotional stress in 3 (25%),post vocal cord sur-
gery in 1(8%), hemiarthroplasty in 1(8%), cervical spine surgery in
1(8%), cervical trauma in 1(8%), gastrointestinal infection in 1 (8%),
road side accident in 1(8%). Presenting symptomswere; chest pain
or discomfort in 3 (25%), NYHA grade III/IV dyspnoea in 9(75 %)
patients. 7 (58%) patients had elevated creatine kinase MB and
troponin T levels, but the levels were usually only marginally
elevated. Electrocardiographic changes observed were ST-
segment elevation in 3 (25%), pathological Q waves in 3(25%),
mainly in the leads V1-4.ST-segment depression was found in 4
patients (30%),3 patients (25%) exhibited T-wave inversion
without ST-segment shift.3 patients presented with cardiogenic
shock and 1 patient with ventricular tachycardia. Echocardio-
graphic parameters mean ± SD LV end-diastolic volume was
(115.9±4.0 mL) mean ± SD LV ejection fraction was (28.2%±2.5%).
None of the patients had an E/Em ratio of more than 15. In all 12
patients, left ventricular systolic function recovered completely
within three weeks. The systolic strain rate was decreased from
base to apex, but the early diastolic strain rate from base to apex
was marginally reduced (+3±0.5).
Conclusion: In patients with suspected ABS, clinical history of
acute physical/emotional stress with ECG changes mimicking
ischemia/infarct, echocardiographic systolic/diastolic paradox
with or without contrast echocardiography is helpful in catego-
rization of these patients.
Study of the role of ivabradine in acute heart
failure
Vikas Singh, Pramod Kumar, Ajay Kr Sinha
Paras HMRI Hospital, India
Background: Ivabradine is a drug which acts by selectively
blocking If current in the SA Node. It is approved for use in chronic
congestive heart failure. In patients with acute decompensated
systolic heart failure, tachycardia could be either a compensatory
mechanism or contribute to worsening heart failure. There are
situations where using a beta blocker is not an option.The present
study was planned to assess the feasibility, safety and efficacy of
using Ivabradine in acute heart failure.
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